re-reading PYC's presentations it seems they are definitely shooting for 2 trials vs. 3. How likely this is I don't know.
"These designations could streamline
VP-001 and PYC-001 paths to market with
the potential for a single pivotal study in both
programs (2 clinical trials rather than 3)"
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.25 |
Change
-0.055(4.23%) |
Mkt cap ! $726.1M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.26 | $1.24 | $173.1K | 139.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 33352 | $1.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 7691 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| PYC (ASX) Chart |